MARKET

IDYA

IDYA

Ideaya Biosciences
NASDAQ
30.46
-1.63
-5.08%
After Hours: 30.46 0 0.00% 16:34 03/27 EDT
OPEN
31.90
PREV CLOSE
32.09
HIGH
32.05
LOW
30.36
VOLUME
693.96K
TURNOVER
--
52 WEEK HIGH
39.28
52 WEEK LOW
13.45
MARKET CAP
2.67B
P/E (TTM)
-23.7061
1D
5D
1M
3M
1Y
5Y
1D
IDEAYA Biosciences grants 49,000 inducement stock options; exercise price set at $32.09
Reuters · 1d ago
IDEAYA BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 1d ago
Does IDEAYA (IDYA) Use OptimUM-02 Timing To Reframe Its Core Clinical Pipeline Story?
Simply Wall St · 2d ago
Assessing IDEAYA Biosciences (IDYA) Valuation After Recent Share Price Weakness
Simply Wall St · 4d ago
IDEAYA slips on delaying results from darovasertib uveal melanoma trial
Seeking Alpha · 5d ago
Ideaya Biosciences updates guidance related to timing of Phase 2/3 data release
TipRanks · 5d ago
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA), Tarsus Pharmaceuticals (TARS) and Insmed (INSM)
TipRanks · 5d ago
Ideaya Biosciences falls -6.0%
TipRanks · 5d ago
More
About IDYA
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).

Webull offers Ideaya Biosciences Inc stock information, including NASDAQ: IDYA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IDYA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IDYA stock methods without spending real money on the virtual paper trading platform.